AGP Executive Report
Last update: 5 hours agoBiotech Deal Shock: Bristol Myers Squibb and China’s Hengrui Pharma just announced a global collaboration worth up to $15.2B, covering 13 early-stage oncology, hematology, and immunology programs—BMS pays $600M upfront and more in milestones as the partners race to build new pipelines ahead of major patent expiries. Macau Health Alert: The Health Bureau (SSM) reported a serious Legionnaires’ disease case in an 83-year-old man, now in ICU, pushing this year’s total to six. Mosquito & Dengue Risk: SSM warned Macau’s mosquito breeding index jumped in April, raising dengue and chikungunya risk as travel and weather fuel Aedes growth. Local Prevention Push: Govt says it will provide mosquito repellents at 12 parks and rest areas. Healthcare Spotlight: International Healthcare Week opens in Hong Kong, spotlighting healthcare breakthroughs and smart health tech. Gaming Diversification: At G2E Asia, MGM’s Kenneth Feng said Macau suite products can yield up to 5x the revenue of a regular room, as operators rebalance high-end offerings.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result.
Perspectify News
![<![CDATA[Bristol Myers Squibb, Hengrui Pharma Form $15.2 Billion Strategic Drug Development Collaboration]]>](https://cdn.sanity.io/images/0vv8moc6/pharmexec/92b02a7f6e0c466c155a40ec32a74d94a075d09b-1280x720.jpg)
